Although anti-VEGF (vascular endothelial growth factor) therapy with bevacizumab failed in GBM patients, its combination with angiopoietin-2 (Ang-2) inhibition led to M2-to-M1 reprogramming in the tumor microenvironment and prolonged survival in glioma-bearing mice (Yu et al., 2016). This evidence concerns the gene ANGPT2 and glioblastoma.